A guideline for the management of gastrointestinal stromal tumour (GIST)

Sarcoma

Volumn 6, Issue 3, 2002, Pages 83-87

  Judson, Ian ^a,h   Leahy, Michael ^b   Whelan, Jeremy ^c   Lorigan, Paul ^d   Verrill, Mark ^e   Grimer, Robert ^f   Robinson, Martin ^g  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^c MIDDLESEX HOSPITAL   (United Kingdom)

^d CHRISTIE HOSPITAL   (United Kingdom)

^e NEWCASTLE GENERAL HOSPITAL   (United Kingdom)

^f ROYAL ORTHOPAEDIC HOSPITAL   (United Kingdom)

^g WESTON PARK HOSPITAL   (United Kingdom)

^h INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB;

ACCURACY; ADVANCED CANCER; ANEMIA; ARTICLE; CANCER INHIBITION; CLINICAL TRIAL; DRUG EFFICACY; DRUG RESPONSE; EDEMA; FATIGUE; FEASIBILITY STUDY; GASTROINTESTINAL STROMAL TUMOR; GASTROINTESTINAL SURGERY; GASTROINTESTINAL TRACT; HUMAN; MESENCHYME; METASTASIS; NAUSEA; PALLIATIVE THERAPY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RASH; SARCOMA; SKILL; TUMOR LOCALIZATION; VOMITING;

EID: 0036764761     PISSN: 1357714X     EISSN: None     Source Type: Journal    
DOI: 10.1080/1357714021000045217     Document Type: Article

References (12)

1. Kindblom L-G, Remotti HE, Aldenborg F, et al. Gastrointestinal pacemaker cell tumour (GIPACT): Gastrointestinal stromal tumours show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol 1998; 152: 1259-69.
2. Sircar K, Hewlett BR, Huizinga JD, et al. Interstitial cells of Cajal as precursors of gastrointestinal stromal tumours. Am J Surg Pathol 1999; 23: 377-89.
3. Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998; 279; 577-80.
4. Van Glabbeke M, van Oosterom AT, Oosterhuis JW, et al. Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcomas: An analysis of 2,185 patients treated with anthracycline-containing first-line regimens - A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. J Clin Oncol 1999; 17: 150-7.
5. Platt BE, Hollema H, Molenaar WM, et al. Soft tissue leiomyosarcomas and malignant gastrointestinal stromal tumours: Differences in clinical outcome and expression of multidrug resistance proteins. J Clin Oncol 2000; 18: 3211-20.
6. Blanke CD, von Mehren M, Joensuu H, et al. Evaluation of the safety and efficacy of an oral molecularly-targeted therapy, STI571, in patients with unresectable or metastastic gastrointestinal stromal tumours (GISTs) expressing C-KIT (CD117). Am Soc Clin Oncol 2001; 20; Abstr 1a.
7. Van Oosterom AT, Judson I, Verweij J, et al. for the European Organisation for Research into Treatment for Cancer (EORTC), Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours; a phase I study. Lancet 2001; 358: 1421-3.
8. Van Oosterom AT, Judson I, Verweij J, et al. Update of the imatinib (STI571, Glivec) phase I study in gastrointestinal stromal tumours (GISTs) Proc Am Soc Clin Oncol 2002; Abstr 327.
9. Judson IR, Verweij J, van Oosterom A, et al. Imatinib (Gleevec) an active agent for gastrointestinal stromal tumors (GIST), but not for other soft tissue sarcoma (STS) subtypes not characterized for KIT and PDGF-R expression results of EORTC Phase II studies. Proc Am Soc Clin Oncol 2002; Abstr 1609.
10. Demetri G, Rankin C, Fletcher C, et al. Phase III randomised study of imatinib mesylate (Gleevec, STI571) for GIST: Intergroup SOO33 early results. Proc Am Soc Clin Oncol 2002; Abstr 1651
11. Casali PG, Verweij J, Zalcberg J, et al. Imatinib (Glivec) 400 mg vs 800 mg daily in patients with gastrointestinal stromal tumours (GIST) a randomised phase III trial from the EORTC Soft Tissue and Bone Sarcoma Group, the Italian Sarcoma Group (ISG) and the Australasian Gatro-Intestinal Trials Group (AGITG). A toxicity report. Proc Am Soc Clin Oncol 2002; Abstr 1650.
12. Nielsen TO, West RB, Linn AC, et al. Molecular characterisation of soft tissue tumours: A gene expression study. Lancet 2002; 359: 1301-7.